RadNet stock
RDNTNASDAQRadNet, Inc., HealthcareISIN US7504911022
44Score 44 out of 100, Weak
Price and trend
85 / 100
Price history
+2.1% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 16% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 10.0% below its 52-week high. Largest decline in 20 years: 91% (July 2007 to March 2009).
Chart figures for advanced users
- SMA 50$72.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$65.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$51.87
- The lowest closing price of the last twelve months.
- Resistance$84.48
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- RadNet, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $5.98B, is number 22 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.04B (up 11.5% year on year) and a loss of $18.65M.
- For fiscal 2026, analysts expect on average revenue of $2.51B (up 23%) and adjusted earnings per share of $0.51 (up 114.3%).
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 479 of 702 in Healthcare, median 53.
- Our model puts fair value at $21.26, with the price 258% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 33.1% a year through 2028 (estimates from 5 analysts).Growth 53
- Growing faster than its industryRevenue up 13.7% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 53
Weaknesses
- Above fair valuePrice 258% above the fair value of $21.26.Valuation 16
- DilutionShare count up 48% since 2020.Capital allocation 22
- Loss-makingLoss of $22.38M over the last 12 months.Fundamentals 49
Its standout strengths are technical analysis and momentum, while valuation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $15.19 and expensive above $35.44 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 10.5%. At 11.5% the fair value would be $18.26, at 9.5% it would be $25.35.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 21.1% on the twelve months before. Revenue has grown strongly since 2005, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 4%, operating 4%, net −1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 8 Nov 2026EPS reported $0.30 (expected $0.22)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.510.0%
- Revenue
- $2.51B0.0%
- Earnings per share
- $0.90+0.9%
- Revenue
- $2.83B+1.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.5%2026 imaging center guidance raised: revenue of $2.37 to $2.42 billion (up $15 million), adjusted EBITDA of $345 to $358 million (up $5 million) and free cash flow of $115 to $125 million (up $3 million).
“Total net revenue guidance for the imaging center segment increased to a range of 2.37 billion to $2.42 billion an increase of $15 million at both the low and high end of the range as compared with the guidance we provided after our first quarter results.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $6.49M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Patel MitalSale
11 Nov 2026, EVP, Chief Operating Officer
- Shares
- 44,661
- Price
- $78.51
- Value
- $3.51M
- Swartz David LSale
18 Jun 2026, Board
- Shares
- 2,699
- Price
- $53.89
- Value
- $145,449
- Wesdorp CornelisSale
16 Jun 2026, Pres & CEO, Digital Health
- Shares
- 4,750
- Price
- $58.11
- Value
- $276,023
Show 1 more
- Forthuber Stephen MSale
15 Jun 2026, Pres & CEO-Eastern Operations
- Shares
- 44,067
- Price
- $58.16
- Value
- $2.56M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at RadNet
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- ICON PublicICLR $15.02B62
- bioMérieuxBIM.PA $12.04B70
- WuXi XDC Cayman2268.HK $11.58B74
- QiagenQGEN $10.35B75
- GRAILGRAL $5.46B43
- DiaSorinDIA.MI $5.3B67
- BillionToOneBLLN $5.29B64
- Sotera HealthSHC $4.65B54
ETFs that hold RadNet
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 1.46% | 0.89% | €11.72M |
| iShares Ageing Population UCITS ETF2B77 | 0.50% | 0.40% | €813.42M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.32% | 0.30% | €2.31B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.19% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.19% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.07% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.